Tazverik (Tazemetostat Hydrobromide) Patent Expiration, LOE Window & CMS Spending

Tazverik (Tazemetostat Hydrobromide) by Epizyme: FDA Orange Book core substance LOE 2034-01-23 (last listed 2038-05-03), 0 AB generics, $28.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEpizyme
FDA Application & PathwayN213400 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-01-23
Last Listed Patent or Exclusivity Date2038-05-03
Orange Book Patents (*PED Extensions)27 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$28.8M
2024 Medicare Part D Spend$25.1M
2024 Medicaid Spend$3.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel